Can a Lower Dose of Everolimus Work Just as Well for Advanced Neuroendocrine Tumors?

Table of Contents

• Key Points
• Why This Research Matters
• Everolimus at a Glance: How the Drug Works
• The Problem with the Standard 10 mg Dose
• Study Methods: How the Research Was Conducted
• Who Was in the Study: Patient Characteristics
• Key Finding: Time on Treatment Before Failure
• Key Finding: Overall Survival
• Side Effects and Treatment Discontinuation
• What These Findings Mean for Patients
• Study Limitations: What This Research Couldn't Prove
• Recommendations for Patients and Doctors
• The Future: The EVENET Randomized Trial
• Frequently Asked Questions
• Source Information

Key Points

• In a retrospective study of 92 patients, lower-dose everolimus (5–6 mg daily) led to time to treatment failure similar to higher-dose (7–10 mg daily), with no significant difference.
• Median time to treatment failure was 9.2 months for higher dose and 7.2 months for lower dose, but this difference was not statistically significant.
• Overall survival was not significantly different between dose groups after adjusting for age, tumor grade, and treatment line.
• Lower dosing may cause fewer severe side effects and lower drug costs, especially for older or frailer patients, but this is not proven.
• A randomized phase II trial called EVENET is currently testing whether 10 mg daily and 5 mg daily are similar in controlling advanced neuroendocrine tumors.

Why This Research Matters

Neuroendocrine tumors (NETs) are uncommon cancers that develop from neuroendocrine cells—cells that act like nerve cells and hormone-producing cells at the same time. These tumors can arise in the gastrointestinal tract (stomach, intestines, pancreas), the lungs, or other areas. When they cannot be removed by surgery and have spread (metastasized), they are called advanced NETs.

For many years, doctors have relied on a drug called everolimus to slow the growth of these tumors. The drug works by blocking a protein pathway inside cancer cells called the mTOR pathway, which tumors depend on to grow and multiply.

The catch is dosage. The only randomized trials that proved everolimus works used a dose of 10 mg taken by mouth once daily. That dose is effective, but it is also toxic. Nearly 25% of patients experience serious side effects—a number that climbs even higher in real-world settings, where patients tend to be older and sicker than those enrolled in clinical trials.

This study asked a practical question that matters directly to patients: Can a lower dose—5 to 6 mg per day—control the tumor just as well as the standard 10 mg dose, while being easier for patients to tolerate?

Everolimus at a Glance: How the Drug Works

Everolimus is an oral medication that belongs to a class of drugs called mTOR inhibitors. The mTOR pathway acts like a switchboard inside cells, telling them when to grow and divide. In many NETs, this pathway is hyperactive, driving tumor growth.

By shutting down that switchboard, everolimus can slow or stop tumor progression. It is approved as a second-line or later treatment for patients with well-differentiated NETs of the gastrointestinal tract, lungs, or pancreas. Compared with a placebo (inactive pill), everolimus significantly extended the time patients lived without their cancer worsening—a measure called progression-free survival (PFS). This was demonstrated in patients with advanced pancreatic NETs and with gastrointestinal or lung NETs.

The drug works at multiple dose levels, but the treatment effect at lower doses was not previously well understood in daily practice.

The Problem with the Standard 10 mg Dose

The standard approved dose of everolimus is 10 mg taken once daily. At that dose, clinically relevant side effects occur in about half of all patients in clinical trials. The most common side effects of any severity include:

• Mouth sores (stomatitis): experienced by 65% of patients
• Skin rash: experienced by 50% of patients
• Infections, diarrhea, nausea, and fatigue: each affecting roughly one-third of patients

Serious side effects—classified as grade 3 or higher, meaning severe or life-threatening—occur in a significant minority of trial participants. Specific grade 3+ rates from the randomized trials were:

• Mouth sores: 9%
• Diarrhea: 7%
• Infections: 7%
• Anemia (low red blood cell count): 6%
• High blood sugar (hyperglycemia): 5%
• Fatigue: 3%

Real-world data show even higher rates of severe toxicity. Studies report everolimus-induced pneumonitis (an inflammatory lung condition) in nearly 20% of patients at any grade, with severe grade 3–4 pneumonitis in about 8%. The authors of this study previously published a multicenter review in which 22% of patients had severe (grade 3–4) infections, 6% had opportunistic infections (infections that take advantage of a weakened immune system), and 3.6% of patients died from treatment-related causes.

Why are real-world rates higher than trial rates? The authors explain that everyday patients tend to have more coexisting medical conditions (comorbidities) and are more fragile. They also may be followed for much longer—nearly double the follow-up time of the phase III trials (17–33 months)—giving side effects more time to emerge.

Faced with this toxicity, clinical trials have always built in two dose-reduction steps: from 10 mg down to 5 mg daily, and from 5 mg daily down to 5 mg every other day. Treatment interruptions of up to 4 weeks are also allowed. Even with these maneuvers, side effects forced 12% to 24% of patients to stop everolimus entirely in the phase III trials.

Study Methods: How the Research Was Conducted

Researchers at two Brazilian cancer centers—A.C. Camargo Cancer Center in São Paulo and Hospital Moinhos de Vento in Porto Alegre—conducted this multicenter retrospective study. They identified patients by searching medical records from August 2011 to September 2023.

To be included, patients had to meet all of the following criteria:

• Age 18 or older
• Histologically confirmed, locally advanced, or metastatic NET that could not be removed surgically
• Primary tumor origins in the gastroenteropancreatic tract, lung, or unknown origin (if suspected to be gastroenteropancreatic based on pathology tests called immunohistochemistry)
• Well-differentiated histology of any grade, using the 2019 World Health Organization (WHO) classification system
• Measurable disease according to the RECIST v1.1 criteria (a standardized way of measuring tumor response)
• Radiologically progressive tumors before starting everolimus
• At least one dose of everolimus received

Patients with NETs of gynecologic or urologic origins, and those with mixed neuroendocrine/non-neuroendocrine tumors, were excluded. Patients with carcinoid syndrome (a condition caused by tumors secreting hormones) were allowed to take somatostatin analogs—medications that control hormone symptoms—at the same time as everolimus.

Because many patients who start at 10 mg daily later need their dose lowered, the investigators did something thoughtful. Instead of grouping patients by their starting dose, they calculated the mean (average) daily dose each patient actually took during the entire treatment duration. Patients were then divided into two groups:

• Higher-dose (HD) group: mean daily dose of 7–10 mg
• Lower-dose (LD) group: mean daily dose of 6 mg or less

The primary endpoint was time to treatment failure (TTF)—the time from the first day of treatment until the tumor progressed, the drug was stopped because of toxicity or intolerance, or the patient died from any cause. TTF is a combined measure: it reflects both whether the drug is keeping the tumor in check and whether the patient can tolerate it well enough to keep taking it.

The investigators also measured overall survival (OS) as a secondary endpoint, calculated from the start of everolimus until death or last follow-up. Statistical analyses used Cox regression models to adjust for known prognostic factors: age, tumor grade, and line of therapy (whether everolimus was given as first/second-line treatment or third-line and beyond). Two-sided p-values below 0.05 were considered statistically significant.

Dose reductions were made by the treating physician. They could be made upfront (for frailty or older age) or during treatment when side effects emerged. Notably, 55% of patients in the LD group had started at a higher dose and reduced it, while 45% began at a low dose from the start.

The study was approved by the ethics committee at each institution (A.C. Camargo Cancer Center approval code 5.949.520). Because of the retrospective design, signed informed consent from individual patients was not required.

Who Was in the Study: Patient Characteristics

A total of 92 patients were included. Of these, 74 patients (80%) were in the higher-dose (HD) group, taking a median daily dose of 10 mg (range 6.8–10 mg). 18 patients (20%) were in the lower-dose (LD) group, taking a median daily dose of 5.1 mg (range 4.7–6 mg).

The two dose groups were similar in most baseline characteristics, but there were two important differences:

• Age: Patients in the LD group were significantly older. The median age was 68 years (range 27–87) in the LD group versus 53 years (range 25–82) in the HD group (p = 0.007). This makes sense: frailer, older patients were more likely to start low or have doses reduced.
• Tumor grade: The LD group had more grade 3 tumors (28% versus 18%; p = 0.003). Grade 3 NETs are faster-growing tumors with higher Ki-67 proliferation indices.

Other baseline characteristics were balanced between groups:

• Sex: 63% of the HD group was male, versus 61% in the LD group (p = 0.8)
• ECOG performance status (a measure of physical function, where 0 means fully active): In the HD group, 57% had a score of 0; in the LD group, 78% had a score of 0 (p = 0.1)
• Primary tumor site: Pancreatic NETs in 58% of HD patients and 56% of LD patients; gastrointestinal or other origins in the remainder (p = 0.8)
• Treatment line: Everolimus was given as first or second-line therapy in 65% of HD patients and 56% of LD patients; 35% and 44% received it as third-line or later, respectively (p = 0.46)

Eight patients (9% of the total) started everolimus at 5 mg from the beginning because of older age and/or frailty; one of these patients needed a further reduction to 5 mg every other day.

Dose reductions during treatment (not upfront) were needed in 12 (16%) of HD patients and 10 (55%) of LD patients.

Key Finding: Time on Treatment Before Failure

The central result was a tie.

At a median follow-up of 4.2 years, the median time to treatment failure (TTF) was:

• 9.2 months (interquartile range [IQR]: 3.7–32) for the higher-dose (HD) group
• 7.2 months (IQR: 3.9–27) for the lower-dose (LD) group

The difference was not statistically significant (log-rank p = 0.85). In statistical terms, a p-value of 0.85 means there is an 85% probability that any observed difference arose purely by random chance—essentially, the two groups performed about the same.

The statistical analysis comparing the two groups directly confirmed this. The hazard ratio (HR)—a measure of how likely one group is to experience treatment failure at any given time compared with the other—was 1.24, with a 95% confidence interval (CI) of 0.68 to 2.25 and a p-value of 0.47. A hazard ratio of 1.24 suggests that LD patients failed treatment about 24% faster than HD patients, but the wide confidence interval (which spans from 0.68 to 2.25) crosses 1.0, meaning the difference cannot be distinguished from pure chance.

After adjusting for age at the start of treatment (HR 1.02; 95% CI 1.01–1.04; p = 0.002), tumor grade when comparing grade 3 versus grade 1/2 (HR 1.27; 95% CI 0.95–1.71; p = 0.11), and treatment line when comparing third-line or later versus first/second-line (HR 1.55; 95% CI 0.92–2.62; p = 0.09), the dose group still showed no significant effect.

The authors performed an extra check. Because everolimus is formally approved only for patients with grade 1 or grade 2 NETs, they repeated the TTF analysis after excluding the 17 patients with grade 3 tumors. The results stayed similar: the median TTF was 5.3 months in the LD group versus 9.2 months in the HD group, again not statistically significant (log-rank p = 0.92). The median Ki-67 index—a marker of how fast tumor cells divide—in the excluded grade 3 group was 30%.

Key Finding: Overall Survival

Overall survival (OS) also showed no statistically significant difference between dose groups, though the numbers tell a somewhat more complicated story.

The median overall survival was:

• 6.5 years (IQR: 1.37–9.98) in the higher-dose group
• 3.6 years (IQR: 1.4–6) in the lower-dose group

The difference was not statistically significant (log-rank p = 0.57). In plain language, although the HD group lived about 2.9 years longer on average, the broad overlap between the groups means we cannot confidently attribute that difference to the dose. The LD group, remember, was older and had more grade 3 tumors—factors that independently shorten survival.

The multivariable Cox model for overall survival confirmed this interpretation. It found that the following factors were independently associated with worse overall survival:

• Older age: HR 1.03; 95% CI 1.01–1.05; p = 0.007 (for each additional year of age)
• Grade 3 tumors (versus grades 1/2): HR 1.68; 95% CI 1.15–2.47; p = 0.008
• Everolimus given in the third line or later: HR 2.15; 95% CI 1.05–4.34; p = 0.036

But the mean daily dose of everolimus itself was not independently associated with survival: HR 1.32; 95% CI 0.56–3.13; p = 0.53. In other words, once you account for who the patients are (their age, tumor aggressiveness, and how many prior treatments they had), the dose of everolimus did not predict how long they lived.

Side Effects and Treatment Discontinuation

Side effects drove treatment discontinuation in both groups, but the patterns differed by dose.

In the higher-dose group, 19 of 74 patients (25.7%) stopped everolimus for various reasons:

• Sixteen patients stopped because of severe toxicities
• One patient stopped due to logistics issues from the health care provider
• One patient chose to stop voluntarily
• One patient stopped after a surgical intervention

Looking in detail at the 16 HD patients who stopped for side effects, the toxicities included:

• Five patients with grade 3/4 infections
• Four patients with grade 3 pneumonitis (lung inflammation)
• One patient with grade 3 stomatitis (mouth sores)
• One patient with both grade 2 stomatitis and persistent grade 2 diarrhea
• Three patients with grade 3 skin rashes (one also having grade 2 diarrhea)
• One patient with severe hepatic steatosis (fatty liver) accompanied by grade 3 liver enzyme elevation and grade 3 dyslipidemia (abnormal blood fats)
• One patient with grade 3 anemia (low red blood cells) and thrombocytopenia (low platelets)

In the lower-dose group, 4 of 18 patients (22.3%) stopped everolimus because of toxicities:

• One patient with grade 2 stomatitis
• Three patients with grade 3 myelotoxicity (suppression of bone marrow function)

A crucial observation: there were no toxicity-related deaths in either group in this study.

The percentages look similar at first glance (25.7% versus 22.3%), but the numbers require context. Most patients in the LD group arrived there because they could not tolerate the higher dose—55% had the dose reduced for toxicity and 45% were started low due to frailty. The fact that these fragile patients did not have higher discontinuation rates is itself a signal that lower doses may be better tolerated.

What These Findings Mean for Patients

This study found no statistically significant difference between low-dose and high-dose everolimus for either time to treatment failure or overall survival. For patients, that possibility is valuable in three concrete ways.

First, quality of life. Everolimus at 10 mg daily brings several burdens—mouth sores in two-thirds of patients, rashes in half, and serious side effects in about a quarter of trial patients. Reducing adverse events not only helps patients feel better day-to-day; it also improves treatment adherence, because patients are more willing to continue a therapy they tolerate well.

Second, cost. In many countries, including Brazil, the price of everolimus is directly proportional to the dose. A patient taking 5 mg daily pays roughly half the drug cost of a patient taking 10 mg. The financial savings extend beyond the drug itself: fewer side effects mean fewer hospitalizations, doctor visits, laboratory tests, imaging scans, and additional medications to manage complications. This is especially important where health care resources are limited, such as in developing and underdeveloped countries.

Third, an individualized approach. The ideal dose of everolimus for any given patient involves factors beyond the tumor itself—nutrition status, kidney function, and liver function all affect how the drug behaves in the body. Some of these factors vary among NET patients in ways that make them a distinctive population compared with other cancer types. For example, NET patients often have better kidney function than patients with renal cell carcinoma but more extensive liver metastases than patients with breast cancer.

Evidence from a Japanese prospective study of patients with renal cell carcinoma found that patients who developed side effects had blood concentrations of everolimus after 8 days of treatment that were twice as high as those who did not experience toxicity. In an early phase I clinical trial of everolimus in patients with solid tumors, certain toxicities—including low platelets, high blood sugar, and diarrhea—occurred only in the 10 mg daily group, not the 5 mg group.

Studies in thyroid cancer, breast cancer, and mixed solid tumors have similarly linked higher blood levels of everolimus with greater toxicity.

The idea of routinely monitoring everolimus blood levels (therapeutic drug monitoring) is unlikely to be tested specifically in NET patients. This remains true because NETs are relatively uncommon and everolimus is now available as a generic drug worldwide. That is precisely why this kind of study—comparing clinically chosen lower doses against the standard dose—is important for guiding everyday care.

Study Limitations: What This Research Couldn't Prove

Every study has limits, and this one has several honest ones worth knowing about.

The biggest limitation is the retrospective design. Researchers looked back at medical records rather than assigning patients randomly to a dose. Retrospective studies carry inherent risks of bias, including selection bias and confounding factors that may drive treatment outcomes.

Concretely, the reasons patients received a lower dose were older age and frailty. That is exactly what the data show: the LD group was much older (median 68 versus 53 years) and had more grade 3 tumors. These are bad-prognosis features, which likely explains the shorter overall survival in the LD group in the unadjusted analysis. The statistical adjustments for age, treatment line, and NET grade tried to compensate, but no statistical model can fully remove this bias. Other unmeasured variables may still have influenced the results.

TTF is an unusual endpoint. Time to treatment failure is not a standard endpoint for evaluating solid tumor therapies; progression-free survival would be more typical. But TTF holds a special value here: it captures the net effect of treatment by combining both disease control and the patient's ability to tolerate therapy. Additionally, the authors note that in a retrospective chart review, progression-free survival is hard to estimate accurately because the intervals between imaging scans vary widely from patient to patient, and objective measurement of tumor responses and progression is often difficult.

The sample size was modest. With 92 patients total—only 18 in the lower-dose group—the study may have been underpowered. That means it might have been unable to detect small but real differences between the dose groups. The wide confidence intervals (for example, HR for TTF ranging from 0.68 to 2.25) tell the same story: we cannot rule out a modest benefit or harm from lower dosing.

Finally, this was not a study of a single dose. The "lower dose" group was defined loosely as a mean daily dose of 6 mg or less, and the actual doses varied. Clinical decisions about dose reductions were left to individual physicians, with no standardized protocols.

Despite all these caveats, the authors emphasize that the results align with earlier phase I trial biology showing that 5 mg daily effectively inhibits the mTOR pathway, and they generate a strong hypothesis that deserves formal testing.

Recommendations for Patients and Doctors

Authors of a retrospective study are careful not to overreach. They present their suggestions as practical guidance informed by the data, not by definitive proof. Their recommendations are worth stating clearly:

1. For older and frailer patients: Starting everolimus at 5 mg daily is a sensible choice. The available evidence does not show a meaningful loss of disease control, while the lower starting dose is less likely to trigger the severe side effects that bedevil the 10 mg dose.
2. For fit patients: Doctors can start treatment at the standard 10 mg daily, but they should take a flexible approach to dose intensity. Rather than waiting for a grade 3 or 4 toxicity to erupt, clinicians should reduce the dose to 5 mg daily as soon as grade 2 side effects appear.
3. For everyone: The results should not be interpreted as proof that 10 mg and 5 mg are perfectly interchangeable in every patient. The data support the possibility of near-equivalence, not equivalence. Individualized dose decisions, based on a patient's age, general condition, tumor grade, and how well they tolerate early side effects, remain essential.

No patient should change their everolimus dose on their own. Any dosage adjustment must be directed by the treating oncologist, who can weigh the specific details of that patient's disease and health status.

The Future: The EVENET Randomized Trial

The authors emphasize that their findings are hypothesis-generating—they set the stage for a more rigorous test, not a final answer. That test is already underway.

The EVENET trial is a randomized phase II trial designed to test near-equivalence between two doses of everolimus. It compares 10 mg daily versus 5 mg daily in patients with advanced, previously treated grade 1 or grade 2 gastroenteropancreatic or lung NETs. The trial registration number is NCT06472388, and its primary endpoint is the progression-free survival rate at 12 months.

If the EVENET trial confirms what this retrospective study suggests, the implications would ripple outward. A strategy of lower-dose everolimus could effectively treat NETs with reduced toxicity, at lower cost, and could expand worldwide access to a drug that is already off-patent. For patients in countries with constrained health care budgets, that could be transformative.

Conclusion

This multicenter retrospective study of 92 patients with advanced neuroendocrine tumors found that a mean daily dose of 5–6 mg of everolimus produced a time to treatment failure statistically indistinguishable from the standard 7–10 mg dose (median 7.2 months versus 9.2 months; p = 0.85). Overall survival was also not significantly different after adjusting for age, tumor grade, and treatment line. Because lower-dose treatment is plausibly associated with less toxicity and lower costs, the authors conclude that everolimus at roughly 5 mg daily may offer a favorable balance of benefit and burden for selected patients—particularly older, frailer individuals. The randomized EVENET trial (NCT06472388) is now testing this hypothesis prospectively.

Frequently Asked Questions

What is everolimus and how does it work for neuroendocrine tumors?

Everolimus is an oral medication that blocks a protein pathway inside cancer cells called the mTOR pathway. This pathway helps tumors grow and multiply. By shutting it down, everolimus can slow or stop tumor progression. It is used for advanced well-differentiated neuroendocrine tumors of the gastrointestinal tract, lungs, or pancreas.

Why is the standard 10 mg dose of everolimus a problem?

The approved dose is 10 mg once daily. In clinical trials, serious side effects occur in about one in four patients. Common side effects include mouth sores in 65% of patients, skin rash in 50%, and infections, diarrhea, nausea, or fatigue in about a third. Real-world severe toxicity rates are even higher.

What question did this study ask about everolimus dose?

It asked whether a lower dose of everolimus, about 5 to 6 mg daily, controls advanced neuroendocrine tumors just as well as the standard 7 to 10 mg daily dose. The study also considered whether lower dosing could cause fewer side effects and lower costs for patients.

How did researchers compare the higher and lower dose groups?

They reviewed records of 92 patients at two Brazilian cancer centers. They calculated the average daily dose each patient actually took during treatment, then divided patients into a higher-dose group (7–10 mg daily, 74 patients) and a lower-dose group (6 mg or less daily, 18 patients). Follow-up lasted a median of 4.2 years.

What does 'not statistically significant' mean in this context?

It means the small difference between the dose groups could easily have happened by chance. This study could not prove that the lower dose is worse or better than the higher dose. It suggests the lower dose may be equally effective, but more research is needed to confirm.

Should I change my everolimus dose based on this study?

No. Do not change your dose on your own. Any adjustment must be directed by your oncologist, who knows your cancer, age, overall health, and side effects. The authors suggest that older or frailer patients might sensibly start at 5 mg daily, but a randomized trial is still underway to confirm this.

Should I get a second opinion about lowering my everolimus dose from 10 mg to 5 mg for advanced neuroendocrine tumors?

If your oncologist recommends the standard 10 mg daily dose but you are older, frail, or struggling with side effects, a second opinion can clarify whether a lower 5–6 mg dose is reasonable. In a study of 92 patients, the lower dose showed no statistically significant difference in time to treatment failure (7.2 vs 9.2 months) or overall survival after adjusting for age, tumor grade, and treatment line. Lower dosing may reduce toxicity and cost, but the evidence is retrospective and not definitive. Individualized decisions remain essential. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Efficacy of a lower dose of everolimus in advanced neuroendocrine tumors

Authors: Rodrigo G. Taboada, Angelo B. Brito, Ana Luiza Silva, Rui F. Weschenfelder, and Rachel P. Riechelmann

Journal: Cancers, 2024, Volume 16, Article 3773

DOI: https://doi.org/10.3390/cancers16223773

Affiliations: Department of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil; Oncology Service, Hospital Moinhos de Vento, Porto Alegre, Brazil

Study timeline: Patients treated from August 2011 to September 2023

Ethics approval: A.C. Camargo Cancer Center review board, approval code 5.949.520

Funding: This study was not supported by any funding source.

This patient-friendly article is based on peer-reviewed research. It was written for educational purposes and is not a substitute for individualized medical advice from a qualified health care professional.